<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01410604</url>
  </required_header>
  <id_info>
    <org_study_id>010-08</org_study_id>
    <nct_id>NCT01410604</nct_id>
  </id_info>
  <brief_title>Adipokines in Obese Adolescents With Insulin Resistance</brief_title>
  <official_title>Inflammatory Mediators in Obese Adolescents With Insulin Resistance Following Metformin Treatment: Controlled Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Regional de Alta Especialidad del Bajio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Infantil de Mexico Federico Gomez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Regional de Alta Especialidad del Bajio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare serum concentrations of inflammatory cytokines,
      interleukin 6 (IL-6), High-sensitivity C-reactive protein (hs-CRP), adiponectin, and tumour
      necrosis factor alpha (TNFα), before and after three months treatment with metformin in obese
      adolescents with insulin resistance (IR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The increased prevalence of obesity in pediatric patients is a public health problem
      particularly because of the difficulties involved with changing lifestyles. Current studies
      of obese children and adolescents show increased insulin resistance (IR) and chronic
      inflammatory states. These conditions increase the risk of disability and/or premature death.

      The current treatment schemes for obese children are conservative and are focused on changing
      their lifestyles (exercise and dietary plans). However, metabolic conditions, such as IR,
      dyslipidemia, and inflammatory processes, are perpetuated.

      Metformin is a biguanide that is used for adolescents with diabetes mellitus and polycystic
      ovarian syndrome. Several clinical trials with metformin for obese pediatric patients have
      observed decreases in IR, decreases in weight, and improvements in lipid metabolism.

      Adipose tissue is not only an energy repository, but also plays an immunological role by the
      secretion of cytokines. Both overweight adults and adolescents show decreases in adiponectin
      levels and increases in tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6). IL-6 can
      stimulate the production of high-sensitivity C-reactive protein (hs-CRP), which is considered
      to be a risk marker for the development of cardiovascular disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Change from baseline in Adiponectin after 3 months of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High-sensitivity C-reactive Protein</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Change from baseline in High-sensitivity C-reactive protein after 3 months of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin 6</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Change from baseline in Interleukin 6 after 3 months of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumour Necrosis Factor Alpha</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Change from baseline in Tumour necrosis factor alpha after 3 months of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Change from baseline in Fasting plasma glucose after 3 months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Change from baseline in Fasting insulin after 3 months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Change from baseline in Body Mass Index after 3 months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Change from baseline in Waist circumference after 3 months of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablet of 500 mg oral placebo every 12 hours for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Dabex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet of 500 mg oral placebo every 12 hours for 3 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obesity defined as Body Mass Index (BMI) ≥ percentile 95

          -  Tanner stage ≥ 2

          -  Insulin resistance defined as Basal insulin &gt; 15 µU/mL or Homeostasis Model Assessment
             index (HOMA) &gt; 4.5

          -  Patients' parents signed written consents when they and their adolescent children
             agreed to enroll

        Exclusion Criteria:

          -  Glucose intolerance

          -  Diabetes mellitus (type 1 or 2)

          -  Anemia (Hb &lt; 10 g/dL)

          -  Plasma creatinine &gt; 1.4 mg/dL

          -  Abnormal hepatic function

          -  Any associated Disease (Pulmonary, Infection, Autoimmune Disease)

          -  History of lactic acidosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria L Evia-Viscarra, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Regional de Alta Especialidad del Bajío</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edel R Rodea-Montero, Statistician</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Regional de Alta Especialidad del Bajío</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Evelia Apolinar-Jiménez, Nutrition</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Regional de Alta Especialidad del Bajío</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leticia M García-Morales, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Infantil de Mexico Federico Gomez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Constanza Leaños-Pérez, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Infantil de Mexico Federico Gomez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mireya Figueroa-Barrón, Chemestry</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Infantil de Mexico Federico Gomez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dolores Sánchez-Fierros, Chemestry</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Infantil de Mexico Federico Gomez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathalie Muñoz-Noriega, Nutrition</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Regional de Alta Especialidad del Bajío</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan G Reyes-García, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Escuela Superior de Medicina del IPN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Infantil de México Federico Gómez</name>
      <address>
        <city>México</city>
        <state>Distrito Federal</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Alta Especialidad del Bajío</name>
      <address>
        <city>León</city>
        <state>Guanajuato</state>
        <zip>37670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). CDC grand rounds: childhood obesity in the United States. MMWR Morb Mortal Wkly Rep. 2011 Jan 21;60(2):42-6. Erratum in: MMWR Morb Mortal Wkly Rep. 2011 Feb 11;60(5):142.</citation>
    <PMID>21248681</PMID>
  </reference>
  <reference>
    <citation>Wilfley DE, Tibbs TL, Van Buren DJ, Reach KP, Walker MS, Epstein LH. Lifestyle interventions in the treatment of childhood overweight: a meta-analytic review of randomized controlled trials. Health Psychol. 2007 Sep;26(5):521-32.</citation>
    <PMID>17845100</PMID>
  </reference>
  <reference>
    <citation>Zeller M, Kirk S, Claytor R, Khoury P, Grieme J, Santangelo M, Daniels S. Predictors of attrition from a pediatric weight management program. J Pediatr. 2004 Apr;144(4):466-70.</citation>
    <PMID>15069394</PMID>
  </reference>
  <reference>
    <citation>Ten S, Maclaren N. Insulin resistance syndrome in children. J Clin Endocrinol Metab. 2004 Jun;89(6):2526-39. Review.</citation>
    <PMID>15181020</PMID>
  </reference>
  <reference>
    <citation>Chiarelli F, Marcovecchio ML. Insulin resistance and obesity in childhood. Eur J Endocrinol. 2008 Dec;159 Suppl 1:S67-74. doi: 10.1530/EJE-08-0245. Epub 2008 Sep 19. Review.</citation>
    <PMID>18805916</PMID>
  </reference>
  <reference>
    <citation>Cruz ML, Weigensberg MJ, Huang TT, Ball G, Shaibi GQ, Goran MI. The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity. J Clin Endocrinol Metab. 2004 Jan;89(1):108-13.</citation>
    <PMID>14715836</PMID>
  </reference>
  <reference>
    <citation>Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Low-grade systemic inflammation in overweight children. Pediatrics. 2001 Jan;107(1):E13.</citation>
    <PMID>11134477</PMID>
  </reference>
  <reference>
    <citation>Freedman DS, Mei Z, Srinivasan SR, Berenson GS, Dietz WH. Cardiovascular risk factors and excess adiposity among overweight children and adolescents: the Bogalusa Heart Study. J Pediatr. 2007 Jan;150(1):12-17.e2.</citation>
    <PMID>17188605</PMID>
  </reference>
  <reference>
    <citation>Beauloye V, Zech F, Tran HT, Clapuyt P, Maes M, Brichard SM. Determinants of early atherosclerosis in obese children and adolescents. J Clin Endocrinol Metab. 2007 Aug;92(8):3025-32. Epub 2007 May 22.</citation>
    <PMID>17519311</PMID>
  </reference>
  <reference>
    <citation>Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998 Jun 4;338(23):1650-6.</citation>
    <PMID>9614255</PMID>
  </reference>
  <reference>
    <citation>Type 2 diabetes in children and adolescents. American Diabetes Association. Pediatrics. 2000 Mar;105(3 Pt 1):671-80. Review.</citation>
    <PMID>10699131</PMID>
  </reference>
  <reference>
    <citation>SEARCH for Diabetes in Youth Study Group, Liese AD, D'Agostino RB Jr, Hamman RF, Kilgo PD, Lawrence JM, Liu LL, Loots B, Linder B, Marcovina S, Rodriguez B, Standiford D, Williams DE. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics. 2006 Oct;118(4):1510-8.</citation>
    <PMID>17015542</PMID>
  </reference>
  <reference>
    <citation>Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 2001 Dec;50(12):1457-61.</citation>
    <PMID>11735093</PMID>
  </reference>
  <reference>
    <citation>Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr. 2008 Jun;152(6):817-22. doi: 10.1016/j.jpeds.2008.01.018. Epub 2008 Mar 19.</citation>
    <PMID>18492523</PMID>
  </reference>
  <reference>
    <citation>Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, Yap F, Ward GM, Cowell CT. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab. 2006 Jun;91(6):2074-80. Epub 2006 Apr 4.</citation>
    <PMID>16595599</PMID>
  </reference>
  <reference>
    <citation>Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc. 2001 Aug;60(3):329-39. Review.</citation>
    <PMID>11681807</PMID>
  </reference>
  <reference>
    <citation>Stefan N, Bunt JC, Salbe AD, Funahashi T, Matsuzawa Y, Tataranni PA. Plasma adiponectin concentrations in children: relationships with obesity and insulinemia. J Clin Endocrinol Metab. 2002 Oct;87(10):4652-6.</citation>
    <PMID>12364452</PMID>
  </reference>
  <reference>
    <citation>Weiss R, Dufour S, Groszmann A, Petersen K, Dziura J, Taksali SE, Shulman G, Caprio S. Low adiponectin levels in adolescent obesity: a marker of increased intramyocellular lipid accumulation. J Clin Endocrinol Metab. 2003 May;88(5):2014-8.</citation>
    <PMID>12727947</PMID>
  </reference>
  <reference>
    <citation>Moon YS, Kim DH, Song DK. Serum tumor necrosis factor-alpha levels and components of the metabolic syndrome in obese adolescents. Metabolism. 2004 Jul;53(7):863-7.</citation>
    <PMID>15254878</PMID>
  </reference>
  <reference>
    <citation>Herder C, Schneitler S, Rathmann W, Haastert B, Schneitler H, Winkler H, Bredahl R, Hahnloser E, Martin S. Low-grade inflammation, obesity, and insulin resistance in adolescents. J Clin Endocrinol Metab. 2007 Dec;92(12):4569-74. Epub 2007 Oct 2.</citation>
    <PMID>17911172</PMID>
  </reference>
  <reference>
    <citation>Cartier A, Lemieux I, Alméras N, Tremblay A, Bergeron J, Després JP. Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-alpha in men. J Clin Endocrinol Metab. 2008 May;93(5):1931-8. doi: 10.1210/jc.2007-2191. Epub 2008 Mar 4.</citation>
    <PMID>18319319</PMID>
  </reference>
  <reference>
    <citation>Ford ES, Galuska DA, Gillespie C, Will JC, Giles WH, Dietz WH. C-reactive protein and body mass index in children: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. J Pediatr. 2001 Apr;138(4):486-92.</citation>
    <PMID>11295710</PMID>
  </reference>
  <reference>
    <citation>Hiura M, Kikuchi T, Nagasaki K, Uchiyama M. Elevation of serum C-reactive protein levels is associated with obesity in boys. Hypertens Res. 2003 Jul;26(7):541-6.</citation>
    <PMID>12924621</PMID>
  </reference>
  <reference>
    <citation>Freedman DS, Sherry B. The validity of BMI as an indicator of body fatness and risk among children. Pediatrics. 2009 Sep;124 Suppl 1:S23-34. doi: 10.1542/peds.2008-3586E.</citation>
    <PMID>19720664</PMID>
  </reference>
  <reference>
    <citation>Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ. 2000 May 6;320(7244):1240-3.</citation>
    <PMID>10797032</PMID>
  </reference>
  <reference>
    <citation>Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11. 2002 May;(246):1-190.</citation>
    <PMID>12043359</PMID>
  </reference>
  <reference>
    <citation>Reaven GM, Chen YD, Hollenbeck CB, Sheu WH, Ostrega D, Polonsky KS. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab. 1993 Jan;76(1):44-8.</citation>
    <PMID>8421101</PMID>
  </reference>
  <reference>
    <citation>Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9.</citation>
    <PMID>3899825</PMID>
  </reference>
  <reference>
    <citation>Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics. 2005 Apr;115(4):e500-3. Epub 2005 Mar 1.</citation>
    <PMID>15741351</PMID>
  </reference>
  <reference>
    <citation>Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001 May;86(5):1930-5.</citation>
    <PMID>11344187</PMID>
  </reference>
  <reference>
    <citation>Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):2005-10. Epub 2001 Feb 6.</citation>
    <PMID>11172066</PMID>
  </reference>
  <reference>
    <citation>Perea-Martinez A, Carbajal R.L, Rodriguez H.R, Zarco R.J, Barrios F.R, Loredo A.A, et al. Association of comorbidity with obesity in mexican children and adolescents. Pediatrics 2008;121(2):S149-S150</citation>
  </reference>
  <reference>
    <citation>Yeh ET. High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. Clin Cardiol. 2005 Sep;28(9):408-12. Review.</citation>
    <PMID>16250263</PMID>
  </reference>
  <reference>
    <citation>Balagopal P, George D, Patton N, Yarandi H, Roberts WL, Bayne E, Gidding S. Lifestyle-only intervention attenuates the inflammatory state associated with obesity: a randomized controlled study in adolescents. J Pediatr. 2005 Mar;146(3):342-8.</citation>
    <PMID>15756217</PMID>
  </reference>
  <reference>
    <citation>Monzillo LU, Hamdy O, Horton ES, Ledbury S, Mullooly C, Jarema C, Porter S, Ovalle K, Moussa A, Mantzoros CS. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res. 2003 Sep;11(9):1048-54.</citation>
    <PMID>12972674</PMID>
  </reference>
  <reference>
    <citation>Huang NL, Chiang SH, Hsueh CH, Liang YJ, Chen YJ, Lai LP. Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation, IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. Int J Cardiol. 2009 May 15;134(2):169-75. doi: 10.1016/j.ijcard.2008.04.010. Epub 2008 Jul 1.</citation>
    <PMID>18597869</PMID>
  </reference>
  <reference>
    <citation>Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001 Oct;108(8):1167-74.</citation>
    <PMID>11602624</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2011</study_first_submitted>
  <study_first_submitted_qc>August 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2011</study_first_posted>
  <results_first_submitted>March 29, 2012</results_first_submitted>
  <results_first_submitted_qc>March 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 23, 2012</results_first_posted>
  <last_update_submitted>April 23, 2012</last_update_submitted>
  <last_update_submitted_qc>April 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Regional de Alta Especialidad del Bajio</investigator_affiliation>
    <investigator_full_name>Maria Lola Evia-Viscarra</investigator_full_name>
    <investigator_title>Pediatrics Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Obesity</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Interleukin six</keyword>
  <keyword>Adiponectin</keyword>
  <keyword>High sensitivity C reactive protein.</keyword>
  <keyword>Tumour Necrosis Factor alpha</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled between January 2007 and December 2009 in the Pediatric Obesity Clinics (POC) from third level Mexican Hospitals: the HMFG, located in the Federal District (country’s capital), and the HRAEB, located in the city of Leon in the state of Guanajauto.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.56" spread="2.25"/>
                    <measurement group_id="B2" value="14.12" spread="1.20"/>
                    <measurement group_id="B3" value="13.37" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adiponectin</title>
        <description>Change from baseline in Adiponectin after 3 months of treatment.</description>
        <time_frame>baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Adiponectin</title>
          <description>Change from baseline in Adiponectin after 3 months of treatment.</description>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="4.29"/>
                    <measurement group_id="O2" value="-7.52" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>High-sensitivity C-reactive Protein</title>
        <description>Change from baseline in High-sensitivity C-reactive protein after 3 months of treatment.</description>
        <time_frame>baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>High-sensitivity C-reactive Protein</title>
          <description>Change from baseline in High-sensitivity C-reactive protein after 3 months of treatment.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" spread="4.40"/>
                    <measurement group_id="O2" value="-1.35" spread="13.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interleukin 6</title>
        <description>Change from baseline in Interleukin 6 after 3 months of treatment.</description>
        <time_frame>baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 6</title>
          <description>Change from baseline in Interleukin 6 after 3 months of treatment.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.09" spread="145.72"/>
                    <measurement group_id="O2" value="16.42" spread="60.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumour Necrosis Factor Alpha</title>
        <description>Change from baseline in Tumour necrosis factor alpha after 3 months of treatment.</description>
        <time_frame>baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Tumour Necrosis Factor Alpha</title>
          <description>Change from baseline in Tumour necrosis factor alpha after 3 months of treatment.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.08" spread="77.58"/>
                    <measurement group_id="O2" value="-4.01" spread="31.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose</title>
        <description>Change from baseline in Fasting plasma glucose after 3 months of treatment.</description>
        <time_frame>baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose</title>
          <description>Change from baseline in Fasting plasma glucose after 3 months of treatment.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="11.39"/>
                    <measurement group_id="O2" value="1.71" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Insulin</title>
        <description>Change from baseline in Fasting insulin after 3 months of treatment.</description>
        <time_frame>baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Fasting Insulin</title>
          <description>Change from baseline in Fasting insulin after 3 months of treatment.</description>
          <units>µU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.97" spread="23.28"/>
                    <measurement group_id="O2" value="11.03" spread="14.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index</title>
        <description>Change from baseline in Body Mass Index after 3 months of treatment.</description>
        <time_frame>baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index</title>
          <description>Change from baseline in Body Mass Index after 3 months of treatment.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="0.83"/>
                    <measurement group_id="O2" value="-0.71" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Circumference</title>
        <description>Change from baseline in Waist circumference after 3 months of treatment.</description>
        <time_frame>baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference</title>
          <description>Change from baseline in Waist circumference after 3 months of treatment.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="4.28"/>
                    <measurement group_id="O2" value="-3.29" spread="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epigastric pain</sub_title>
                <description>Adverse effect characterized by “ burning ” epigastric pain</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>During the recruitment phase, 83 children who were diagnosed with obesity and acanthosis nigricans were evaluated. Of these, 45 did not have the insulin concentration values (&gt;15 µU/mL) required to biochemically define Insulin Resistance.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>M.D. Maria L. Evia-Viscarra</name_or_title>
      <organization>Hospital Regional de Alta Especialidad del Bajio</organization>
      <phone>+52 (477) 267-2000 ext 1405</phone>
      <email>evialola@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

